Interleukin-8 and Interleukin-6 Are Biomarkers of Poor Prognosis in Esophageal Squamous Cell Carcinoma
暂无分享,去创建一个
A. Longatto-Filho | V. Mariano | A. M. Barbosa | E. Torrado | A. Castro | R. Causin | Paula Roberta Aguiar Pastrez
[1] S. Reznik,et al. Update on Management of Squamous Cell Esophageal Cancer , 2022, Current Oncology Reports.
[2] I. Musa,et al. Esophageal cancer epidemiology, diagnosis, and management in Sudan - A review. , 2021, The Medical journal of Malaysia.
[3] I. Soerjomataram,et al. International Trends in Esophageal Squamous Cell Carcinoma and Adenocarcinoma Incidence , 2021, The American journal of gastroenterology.
[4] Yingyong Hou,et al. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma , 2021, JAMA surgery.
[5] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[6] D. Bedognetti,et al. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy , 2021, Molecular cancer.
[7] J. Gibbs,et al. Esophageal cancer: the rise of adenocarcinoma over squamous cell carcinoma in the Asian belt. , 2020, Journal of gastrointestinal oncology.
[8] T. Sunkara,et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors , 2020, Clinical Journal of Gastroenterology.
[9] Alan D. Lopez,et al. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The lancet. Gastroenterology & hepatology.
[10] Mingyao Liu,et al. Chemokines and their receptors as biomarkers in esophageal cancer , 2019, Esophagus.
[11] J. Schlom,et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors , 2019, Journal of Immunotherapy for Cancer.
[12] P. Muszyński,et al. Comparison between clinical significance of serum CXCL-8 and classical tumor markers in oesophageal cancer (OC) patients , 2019, Clinical and Experimental Medicine.
[13] R. Grover,et al. Clinical significance of interleukin-6 in diagnosis of lung, oral, esophageal, and gall bladder carcinomas , 2018, Journal of cancer research and therapeutics.
[14] Q. Tong,et al. Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips , 2018, OncoTargets and therapy.
[15] Jang-Ming Lee,et al. Circulating Interleukin-6 is Associated with Prognosis and Genetic Polymorphisms of MIR608 in Patients with Esophageal Squamous Cell Carcinoma , 2018, Annals of Surgical Oncology.
[16] M. Shaul,et al. Cancer‐related circulating and tumor‐associated neutrophils – subtypes, sources and function , 2018, The FEBS journal.
[17] M. Yashiro,et al. Neutrophils in primary gastric tumors are correlated with neutrophil infiltration in tumor-draining lymph nodes and the systemic inflammatory response , 2018, BMC Immunology.
[18] K. Schalper,et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. , 2017, Cancer treatment reviews.
[19] J. Fregnani,et al. HPV infection and p53 and p16 expression in esophageal cancer: are they prognostic factors? , 2017, Infectious Agents and Cancer.
[20] A. Longatto-Filho,et al. High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer , 2017, PloS one.
[21] A. Longatto-Filho,et al. The Relation of HPV Infection and Expression of p53 and p16 Proteins in Esophageal Squamous Cells Carcinoma , 2017, Journal of Cancer.
[22] Sheng-Jie Yu,et al. Esophageal cancer: Risk factors, genetic association, and treatment. , 2016, Asian journal of surgery.
[23] A. Wikman,et al. Toward improved survivorship: supportive care needs of esophageal cancer patients, a literature review. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[24] D. Forman,et al. The burden of oesophageal cancer in Central and South America. , 2016, Cancer epidemiology.
[25] Dan Xie,et al. Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2 , 2016, Clinical Cancer Research.
[26] Adam J. Bass,et al. The Tumor Microenvironment in Esophageal Cancer , 2016, Oncogene.
[27] W. Mao,et al. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review , 2015, Journal of Cancer.
[28] Jun Zhang,et al. Diagnostic Value of Multiple Tumor Markers for Patients with Esophageal Carcinoma , 2015, PloS one.
[29] T. Omori,et al. Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma. , 2013, Surgery.
[30] D. Ichikawa,et al. Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma. , 2013, Anticancer research.
[31] K. Dvorak,et al. Role of interleukin-6 in Barrett's esophagus pathogenesis. , 2013, World journal of gastroenterology.
[32] B. Mroczko,et al. Interleukin 6 and C-reactive protein in esophageal cancer. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[33] S. Albelda,et al. Tumor-associated neutrophils: friend or foe? , 2012, Carcinogenesis.
[34] G. Sethi,et al. Multifaceted link between cancer and inflammation. , 2012, Bioscience reports.
[35] A. Richmond,et al. Chemokines and chemokine receptors: new insights into cancer-related inflammation. , 2010, Trends in molecular medicine.
[36] E. D. de Vries,et al. Role of chemokines and their receptors in cancer. , 2009, Current pharmaceutical design.
[37] M. Krzystek-Korpacka,et al. Elevation of circulating interleukin-8 is related to lymph node and distant metastases in esophageal squamous cell carcinomas--implication for clinical evaluation of cancer patient. , 2008, Cytokine.
[38] Christopher Chiu,et al. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.
[39] M. Gazouli,et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. , 2005, World journal of gastroenterology.
[40] Megumi Baba,et al. The role of circulating IL‐8 and VEGF protein in the progression of gastric cancer , 2003, Cancer science.
[41] Attila Tárnok,et al. Cytometric bead array to measure six cytokines in twenty-five microliters of serum. , 2003, Clinical chemistry.
[42] W. Wood,et al. Chemokine binding and activities mediated by the mouse IL-8 receptor. , 1995, Journal of immunology.
[43] L. F. Kolakowski,et al. The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. , 1994, The Journal of biological chemistry.
[44] E. Appella,et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor , 1988, The Journal of experimental medicine.
[45] E. Appella,et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[46] D. Forman,et al. Etiology of oesophageal cancer ( C 15 ) in Central and South America , 2016 .
[47] Kaijuan Wang,et al. Serum autoantibodies in the early detection of esophageal cancer: a systematic review , 2014, Tumor Biology.
[48] E. McArthur,et al. Esophageal carcinoma. , 2014, The New England journal of medicine.
[49] J. Luketich,et al. Oesophageal carcinoma , 2013, The Lancet.
[50] Peter D Siersema,et al. Esophageal cancer. , 2008, Gastroenterology clinics of North America.